- Home
- NTIP vs IGC Comparison
NTIP vs IGC Comparison
Compare NTIP & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- IGC
- Stock Information
- Founded
- NTIP 1990
- IGC 2005
- Country
- NTIP United States
- IGC United States
- Employees
- NTIP N/A
- IGC N/A
- Industry
- NTIP Multi-Sector Companies
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- NTIP Miscellaneous
- IGC Health Care
- Exchange
- NTIP Nasdaq
- IGC Nasdaq
- Market Cap
- NTIP 30.8M
- IGC 23.8M
- IPO Year
- NTIP 1998
- IGC N/A
- Fundamental
- Price
- NTIP $1.29
- IGC $0.41
- Analyst Decision
- NTIP
- IGC Strong Buy
- Analyst Count
- NTIP 0
- IGC 2
- Target Price
- NTIP N/A
- IGC $3.63
- AVG Volume (30 Days)
- NTIP 43.4K
- IGC 710.6K
- Earning Date
- NTIP 10-31-2024
- IGC 11-11-2024
- Dividend Yield
- NTIP 7.94%
- IGC N/A
- EPS Growth
- NTIP N/A
- IGC N/A
- EPS
- NTIP N/A
- IGC N/A
- Revenue
- NTIP $1,881,000.00
- IGC $1,062,000.00
- Revenue This Year
- NTIP N/A
- IGC N/A
- Revenue Next Year
- NTIP N/A
- IGC $13.57
- P/E Ratio
- NTIP N/A
- IGC N/A
- Revenue Growth
- NTIP 129.39
- IGC N/A
- 52 Week Low
- NTIP $1.24
- IGC $0.25
- 52 Week High
- NTIP $2.25
- IGC $0.91
- Technical
- Relative Strength Index (RSI)
- NTIP 35.12
- IGC 59.89
- Support Level
- NTIP $1.24
- IGC $0.35
- Resistance Level
- NTIP $1.39
- IGC $0.41
- Average True Range (ATR)
- NTIP 0.06
- IGC 0.02
- MACD
- NTIP -0.00
- IGC 0.00
- Stochastic Oscillator
- NTIP 9.52
- IGC 67.29
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property rights. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.